Describing patterns of care in pancreatic cancer a population-based study

Pancreas

Volumn 44, Issue 8, 2015, Pages 1259-1265

  Burmeister, Elizabeth A ^a,b   O'Connell, Dianne L ^c,d   Beesley, Vanessa L ^a   Goldstein, David ^e,f   Gooden, Helen M ^g   Janda, Monika ^h   Jordan, Susan J ^a   Merrett, Neil D ⁱ   Payne, Madeleine E ^a   Wyld, David ^b,j   Neale, Rachel E ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CANCER RESEARCH DIVISION   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

^j ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

Chemotherapy; Health services; Pancreatic cancer; Patterns of care; Population based; Surgery

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AUSTRALIAN; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT CARE; POPULATION; PRIORITY JOURNAL; QUALITY CONTROL; VERY ELDERLY; AUSTRALIA; HEALTH SURVEY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PANCREATIC NEOPLASMS; PROCEDURES; RADIOTHERAPY; REGISTER; STATISTICS AND NUMERICAL DATA; SURGERY;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; POPULATION SURVEILLANCE; RADIOTHERAPY; REGISTRIES; SURGICAL PROCEDURES, OPERATIVE;

EID: 84930008041     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000384     Document Type: Article

References (42)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2012; Available at: http://globocan.iarc.fr. Accessed September 15, 2014.
2. Cancer Institute NSW. Cancer Incidence and Mortality: Projections 2011 to 2021. Sydney, Australia; 2011.
3. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
4. Revels SL, Banerjee M, Yin H, et al. Racial disparities in surgical resection and survival among elderly patients with poor prognosis cancer. J Am Coll Surg. 2013;216:312-319.
5. Abbott DE, Baker MS, Talamonti MS. Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010;101:315-320.
6. He J, Page AJ, Weiss M, et al. Management of borderline and locally advanced pancreatic cancer: where do we stand? World J Gastroenterol. 2014;20:2255-2266.
7. Kooby DA, Gillespie TW, Liu Y, et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol. 2013: 3634-3642.
8. Verslype C, Van Cutsem E, Dicato M, et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18(Suppl 7):vii1-vii10.
9. Verslype C, Van Cutsem E, Dicato M, et al. The management of metastatic pancreatic cancer:expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. Ann Oncol. 2013:iv5-iv10.
10. NCCN. NCCN Practice Guidelines for Pancreatic Cancer. Version 2.2014. 2014; [obtained on request from NCCN]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/pancreatic.pdf. Accessed September 4, 2014.
11. Race R. National Cancer Patient Experience Survey Programme: All Party Pancreatic Cancer Group. 2013, Quality Health.
12. Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm. 2011;68:573-584.
13. Tempero MA, Berlin J, Ducreux M, et al. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011;22: 1500-1506.
14. Sharp L, Carsin AE, Cronin-Fenton DP, et al. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer. 2009;45:1450-1459.
15. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-1234.
16. Cramb S, Mengerson K, Baade P. Atlas of Cancer in Queensland: Geographical Variation in Incidence and Survival, 1998 to 2007. Brisbane, Australia: Viertel Centre for Research in Cancer Control, Cancer Council Queensland; 2011.
17. Australian Bureau of Statistics. Socio-Economic Indexes for Areas. 2013; [SEIFA]. Available at: http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa. Accessed October 3, 2013.
18. Australian Bureau of Statistics. Remoteness Structure. 2013; [ARIA+]. Available at: http://www.adelaide.edu.au/apmrc/research/projects/category/about-aria.html. Accessed October 3, 2013.
19. Sobin L, Wittekind C. The TNM Classification of Malignant Tumours. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
21. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180.
22. Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012;41: 985-992.
23. Jefford M, Thursfield V, Torn-Broers Y, et al. Use of chemotherapy and radiotherapy in patients with pancreatic cancer in Victoria (2002-2003): a retrospective cohort study. Med J Aust. 2010;192:323-327.
24. Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011;174:1373-1381.
25. SEER. Cancer Statistics Factsheets: Pancreas Cancer. National Cancer Institute. Bethseda, MD. April 2013; Available at: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed February 14, 2014.
26. Australian Institute of Health and Welfare, American Association for Cancer Research. Cancer in Australia: An Overview 2012. Canberra, Australia: Australian Institute of Health and Welfare; 2013.
27. Baxter J, Gray M, Hayes A. Families in regional, rural and remote Australia, in Australian Government: Australian Institute of Family Studies. 2011.
28. Uniting Care, Centre for Social Justice. Fact Sheet 1: 2006 SEIFA Index of Relative Socioeconomic Disadvantage (IRSD) for Queensland. 2010.
29. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation ofthe 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-744.
30. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-15.
31. Speer AG, Thursfield VJ, Torn-Broers Y, et al. Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med J Aust. 2012; 196:511-515.
32. Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol. 2013;107:97-103.
33. Biankin AV, Kench JG, Colvin EK, et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology. 2009;137:558-568 568.e1-568.e11.
34. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
35. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473-1481.
36. eviQ Cancer Treatments Online 2014. Cancer Institute NSW. Available at: https://www.eviq.org.au/Protocol/tabid/66/id/333/view/FullView/Pancreas +Advanced+Gemcitabine.aspx. Accessed June 26, 2014.
37. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369: 1691-1703.
38. Ryska M, Dusek L, Pohnan R, et al. Quality of life is an important factor in the indication in patients with advanced pancreatic carcinoma-a prospective multicentric study [in Czech]. Rozhl Chir. 2012;91:199-208.
39. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
40. David M, Lepage C, Jouve JL, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer. 2009;101:215-218.
41. Goldsbury DE, Smith DP, Armstrong BK, et al. Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study. BMC Health Serv Res. 2011;11:253.
42. Goldsbury DE, Armstrong K, Simonella L, et al. Using administrative health data to describe colorectal and lung cancer care in New South Wales, Australia: a validation study. BMC Health Serv Res. 2012;12:387.